Attenuation Of Hemodynamic Response To Laryngoscopy. Role Of Dexmedetomidine. A Dose Finding Study

• Status: Completed
• Trial end date: 2021-12-13
• Target enrollment: 0
• Participant gender: All

Summary

Two doses of Dexmedetomidine (0.5 µ/kg and 0.75 µ/kg) will be used to attenuate the stress response to laryngoscopy in American Society of Anesthesiology, physical class I patients which will be compared with the placebo-controlled group.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Sindh Institute of Urology and Transplantation
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Age between 18 to 55 years

• ASA I or II patients undergoing surgery under general anaesthesia with endotracheal intubation.

• Patients with Mallampati class I or II.

Exclusion Criteria:

• ASA III & IV patients

• Anticipated or unanticipated difficult intubations which requires more than 15 seconds or more than one attempt.

• Patients with Mallampati class III, IV or with loose teeth.

• Patients with inotropes infusion.

• Patients with known allergy to any anaesthetic agents

• Patients with a heart rate of 60 beats/min or less

• Patients with known hypertension, incidental finding of hypertension while on operating table, diabetes, ischemic heart disease or peripheral vascular disease.

• Pregnant and lactating mothers.